Teikoku Seiyaku’s medicated patches and plasters are currently sold in more than 40 countries worldwide. Lidoderm®, an analgesic plaster for the treatment of post-herpetic neuralgia (PHN) first approved for prescription use in the US, has been marketed by Endo Pharmaceuticals. The equivalent product to Lidoderm® for Europe, the Middle East and South America are marketed by Grünenthal and others, and in Asia by Mundipharma and others.
Our subsidiary in the US conducts post-marketing surveillance and disseminates information about Teikoku Seiyaku. They take full advantage of their location in Silicon Valley, home to scientists and professionals from all over the world, to conduct dynamic research programs. In addition, we acquire product licenses from companies worldwide including those located in the US and France, obtain approval in Japan, and then market the products to healthcare organizations in Japan through our sales partners.
I HOME I WHAT'S TEIKOKU SEIYAKU? I CORPORATE GUIDE I SITE MAP I CONTACT US I
Copyright (C) 2008 All Right Reserved by Teikoku Seiyaku Co.,Ltd.